On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against all other stocks in our database.
Decades of market research shows that the market's biggest winners often have an RS Rating of over 80 as they begin their largest runs.
See How IBD Helps You Make More Money In Stocks
Is Rocket Pharmaceuticals Stock A Buy?
Rocket Pharmaceuticals stock has been rallying off the bottom and approaching its 200-day moving average. The biotech stock is not currently near a potential buying area. See if the stock goes on to form a promising consolidation that could launch a new move. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company showed -50% earnings growth in its most recent report, while sales growth came in at 0%.
Rocket Pharmaceuticals stock earns the No. 250 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Dynavax Technologies and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
